miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue PLoS ONE Année : 2009

miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice.

Résumé

BACKGROUND: Micro RNAs are small, non-coding, single-stranded RNAs that negatively regulate gene expression at the post-transcriptional level. Since miR-143 was found to be down-regulated in prostate cancer cells, we wanted to analyze its expression in human prostate cancer, and test the ability of miR-43 to arrest prostate cancer cell growth in vitro and in vivo. RESULTS: Expression of miR-143 was analyzed in human prostate cancers by quantitative PCR, and by in situ hybridization. miR-143 was introduced in cancer cells in vivo by electroporation. Bioinformatics analysis and luciferase-based assays were used to determine miR-143 targets. We show in this study that miR-143 levels are inversely correlated with advanced stages of prostate cancer. Rescue of miR-143 expression in cancer cells results in the arrest of cell proliferation and the abrogation of tumor growth in mice. Furthermore, we show that the effects of miR-143 are mediated, at least in part by the inhibition of extracellular signal-regulated kinase-5 (ERK5) activity. We show here that ERK5 is a miR-143 target in prostate cancer. CONCLUSIONS: miR-143 is as a new target for prostate cancer treatment.
Fichier principal
Vignette du fichier
journal.pone.0007542.pdf (908.91 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Loading...

Dates et versions

inserm-00431462 , version 1 (12-11-2009)

Identifiants

Citer

Cyrielle Clapé, Vanessa Fritz, Corinne Henriquet, Florence Apparailly, Pedro Luis Fernandez, et al.. miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice.. PLoS ONE, 2009, 4 (10), pp.e7542. ⟨10.1371/journal.pone.0007542⟩. ⟨inserm-00431462⟩
300 Consultations
345 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More